Quick Answer
Yes, severe arthritis can qualify for the Disability Tax Credit Canada in 2026. Rheumatoid arthritis, osteoarthritis, psoriatic arthritis, and ankylosing spondylitis qualify when they markedly restrict walking, dressing, or both at least 90% of the time. The cumulative effect rule often applies when no single activity is fully restricted but several are partially restricted.
CRA Categories for Arthritis
Arthritis claims typically rely on one or more of three categories defined by the Canada Revenue Agency:
- Walking, inability to walk 100 metres on a level surface, even with appropriate aids (cane, walker), without stopping due to pain or breathlessness
- Dressing, inordinate amount of time required to dress oneself due to joint pain, stiffness, or limited grip strength
- Cumulative effect, marked restriction across multiple basic activities (walking + dressing + feeding) that, together, equal a marked restriction in one
Which Arthritis Types Are Most Likely to Qualify?
- Severe rheumatoid arthritis with multiple joint involvement, especially hands, feet, knees, and hips. Often qualifies for both walking and dressing
- Advanced osteoarthritis of weight-bearing joints (hips, knees) causing severe mobility limitation, especially when surgery has been deferred or failed
- Psoriatic arthritis with axial involvement, combined joint and spinal disease creating mobility and dressing limitations
- Ankylosing spondylitis, advanced spinal fusion limiting walking and self-care
- Severe juvenile idiopathic arthritis, marked functional restriction from childhood
Arthritis that is well-controlled on DMARDs or biologics typically does not qualify because the functional limitations are not severe enough.
Key Documentation for Arthritis DTC Claims
- Rheumatology assessment showing diagnosis, affected joints, and disease activity (DAS-28 or similar)
- Specific functional limitations: distance the person can walk, time taken to dress, ability to grip or open containers
- Treatment history: NSAIDs, DMARDs (methotrexate, sulfasalazine), biologics (Humira, Enbrel), corticosteroids, joint injections, joint replacements
- Radiology evidence (X-rays, MRI showing erosions, joint space narrowing, deformity)
- Use of mobility aids (cane, walker, wheelchair) and dressing aids (button hooks, sock aids)
- Records of joint surgeries (replacements, fusions, synovectomy) and post-surgical limitations
The 100-Metre Walking Test
For walking-based arthritis claims, the CRA benchmark is whether the person, even with appropriate aids, can walk 100 metres on a level surface without stopping due to pain or breathlessness. The medical practitioner should specifically address this distance and the reason walking is limited (pain, joint deformity, balance, fatigue).
The Cumulative Effect Rule for Arthritis
Many people with arthritis have moderate restrictions in walking, dressing, and feeding but none reach the marked threshold individually. The cumulative effect rule allows these moderate restrictions to combine. A rheumatologist or family doctor can certify that the combined impact equals a marked restriction in one basic activity.
2026 DTC Amounts for Arthritis
If approved, the federal credit is $1,481 per year. Combined federal plus provincial credit ranges from $2,080 (Ontario) to $3,741 (Quebec). Retroactive claims for up to 10 years of severe arthritis can total $14,000 to $37,000 or more, especially for those approved after years of progressive joint disease.
Real arthritis Filing Scenario
The following example is illustrative. It describes a typical filing flow and does not predict any individual outcome.
A Hamilton resident with seropositive rheumatoid arthritis met with her rheumatologist to complete Part B. The rheumatologist documented bilateral hand and wrist inflammation restricting dressing (45 to 60 minutes required, versus the typical 5 to 10 minutes for someone without the impairment) and walking endurance (limited to short distances before pain forces rest). Part B noted that the restrictions are present even with biologic medication and adaptive tools, persisting at least 90 percent of waking hours. The Notice of Determination arrived 9 weeks after submission, approving the DTC retroactive to 2022.
Documentation That Works for arthritis Part B
What worked in this Part B: a side-by-side time comparison ("45 to 60 minutes versus typical 5 to 10 minutes") and explicit note that the restriction persists despite treatment. CRA reviewers look for both the duration ratio and the "even with treatment" qualifier in rheumatoid arthritis claims. See our cumulative effects rule guide for the technical framework CRA reviewers apply, and our DTC denied appeal guide if a previous application was rejected.
Frequently Asked Questions
Severe osteoarthritis can qualify, especially when weight-bearing joints (hips, knees) are advanced and walking is markedly limited. Mild or moderate osteoarthritis usually does not meet the marked restriction standard.
A rheumatologist provides stronger clinical authority. If your family doctor has been managing your arthritis for years with thorough documentation, they can also certify. For complex cases with biologics or multiple joint surgeries, a rheumatologist's input is preferred.
Possibly, if you still have marked functional restrictions despite treatment. CRA evaluates your functional status with current therapy. Many approved arthritis claims involve people on biologics who continue to have severe mobility or dressing limitations from joint damage that accumulated before effective treatment.
The CRA requires marked restriction at least 90% of the time, but this is judged over time, not by individual days. If your overall pattern, even accounting for better days, shows marked restriction most of the time, you may still qualify. Document this pattern carefully.